美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

225.77

+5.822.65%

盤前：226.530.7600+0.34%04:01 EDT

成交量：52.79萬

成交額：1.18億

市值：243.96億

市盈率：-60.97

高：226.59

開：223.88

低：220.64

收：219.95

資料載入中...

總覽公司新聞公告

百濟神州(06160)因受限制股份單位獲歸屬而發行21.47萬股

百濟神州美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效

百濟神州：關於公司涉及訴訟的進展

百濟神州(06160)美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效

索托克拉上市申請獲受理，百濟神州血液腫瘤管線或迎又一重磅新品

索托克拉上市申請獲受理百濟神州又一款血液腫瘤自研產品有望面市

中国网财经

百濟神州2024年虧損減少至49.8億元，收入增長56.2%

百濟神州4月28日成交額為6230.10萬美元

港股創新藥板塊盤初走高，泰凌醫藥(01011.HK)漲近7%，石藥集團(01093.HK)漲超4%，百濟神州(06160

百濟神州(06160)因受限制股份單位獲歸屬而發行約10.29萬股

百濟神州(688235.SH)發佈2024年度業績，營業收入272.14億元，同比增長56.19%

美股異動 | 百濟神州(ONC.US)漲逾2% 機構：中國內地創新藥出海不受關稅影響

百濟神州4月25日成交額為1.20億美元

“藏頭詩”挑起醫藥暗戰，恆瑞醫藥急了？

达摩财经Pro

康方生物為什麼盯上百濟神州？

百濟神州4月24日成交額為1.18億美元

又一次“頭對頭”勝出！康方生物雙抗藥物療效“擊敗”百濟神州PD-1

百濟神州4月22日成交額為1.81億美元

康方生物在一項臨牀三期試驗中贏了百濟神州的PD-1抗體聯合療法

每日经济新闻

百濟神州(ONC)盤前漲超8% 機構升其目標價至317美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=8"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":225.77,"timestamp":1747339200000,"preClose":219.95,"halted":0,"volume":527903,"hourTrading":{"tag":"盘前","latestPrice":226.53,"preClose":225.77,"latestTime":"04:01 EDT","volume":38,"amount":8608.14,"timestamp":1747382479003},"delay":0,"floatShares":69370116,"shares":108055817,"eps":-3.70325,"marketStatus":"盤前交易","change":5.82,"latestTime":"05-16 05:59:27 EDT","open":223.88,"high":226.59,"low":220.64,"amount":118475918.85832,"amplitude":0.027052,"askPrice":232.12,"askSize":12,"bidPrice":226,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1747402200000},"marketStatusCode":1,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":225.77,"preHourTrading":{"tag":"盘前","latestPrice":226.53,"preClose":225.77,"latestTime":"04:01 EDT","volume":38,"amount":8608.14,"timestamp":1747382479003},"postHourTrading":{"tag":"盘后","latestPrice":225.77,"preClose":225.77,"latestTime":"17:47 EDT","volume":76189,"amount":17201187.86,"timestamp":1747345633414},"volumeRatio":1.2605037401514483,"impliedVol":0.4035,"impliedVolPercentile":0.1739},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":69370116,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":1.2605037401514483,"shares":108055817,"dividePrice":0,"high":226.59,"amplitude":0.027052,"preClose":219.95,"low":220.64,"week52Low":141.31,"pbRate":"6.97","psRate":"5.84","week52High":287.88,"institutionHeld":0,"latestPrice":225.77,"committee":-0.411765,"eps":-3.70325,"divideRate":0,"volume":527903,"delay":0,"ttmEps":-3.70325,"open":223.88,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":235.94,"twentyDayClose":228.14,"sixtyDayClose":236.69},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:8,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531621710","title":"百濟神州(06160)因受限制股份單位獲歸屬而發行21.47萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531621710","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531621710?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:53","pubTimestamp":1745970783,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年4月29日，该公司因根据股权计划授出的受限制股份单位获归属(公司董事除外)而发行21.47万股普通股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","LU0588546209.SGD","06160","LU0307460666.USD","BK1583","BK4139","ONC","BK1161","688235","BK0239","BK1588","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2531120710","title":"百濟神州美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531120710","media":"新浪港股","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531120710?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:47","pubTimestamp":1745970420,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　百济神州（06160）发布公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权后复审程序中受到百济神州质疑的第11，672，803号美国专利的全部权利无效。\n　　2023年11月1日，针对Pharmacyclics就百悦泽®（BRUKINSA®）对百济神州提起的专利侵权诉讼，百济神州向USPTO提交了PGR申请，质疑‘803专利中某些权利的有效性。Pharmacyclics可对USPTO的最终书面决定提出上诉。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-30/doc-ineuwyyy3511637.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","688235","LU0588546209.SGD","06160","BK1588","ONC","BK1583","BK0239","BK4139","BK1161"],"gpt_icon":0},{"id":"2531710813","title":"百濟神州：關於公司涉及訴訟的進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2531710813","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531710813?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:37","pubTimestamp":1745969847,"startTime":"0","endTime":"0","summary":"金融界4月30日消息，百济神州公告称，2023 年 6 月 13 日，Pharmacyclics LLC 公司在美国特拉华州地方法院对百济神州有限公司及公司全资子公司提出申诉，声称公司产品百悦泽®侵犯其专利。2025 年 4 月 29 日，USPTO 作出最终书面决定，宣布 Pharmacyclics 在 PGR 程序中受到公司质疑的‘803 专利的全部权利无效。Pharmacyclics 可提起上诉。本次诉讼目前未对百悦泽®在美国的研发和销售产生不利影响，且预计不会对公司的生产经营产生重大不利影响。\n\n\r\n            责任编辑：栎树","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30073750025781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","688235","LU1969619763.USD","LU0588546209.SGD","BK1500","BK4139","LU2328871848.SGD","BK1161","06160","ONC","BK0239","BK1588","BK1583"],"gpt_icon":0},{"id":"2531127427","title":"百濟神州(06160)美國專利糾紛勝訴 USPTO裁定Pharmacyclics專利無效","url":"https://stock-news.laohu8.com/highlight/detail?id=2531127427","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531127427?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 07:21","pubTimestamp":1745968909,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，美国专利商标局作出了一项最终书面决定，宣布Pharmacyclics LLC在专利授权后复审程序中受到百济神州质疑的第11,672,803号美国专利的全部权利无效。2023年11月1日，针对Pharmacyclics就百悦泽®(BRUKINSA®)对百济神州提起的专利侵权诉讼，百济神州向USPTO提交了PGR申请，质疑‘803专利中某些权利的有效性。Pharmacyclics可对USPTO的最终书面决定提出上诉。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4139","06160","LU2328871848.SGD","BK1583","688235","LU0307460666.USD","BK0239","BK1161","LU1969619763.USD","BK1500","LU0588546209.SGD","ONC"],"gpt_icon":0},{"id":"2531200277","title":"索托克拉上市申請獲受理，百濟神州血液腫瘤管線或迎又一重磅新品","url":"https://stock-news.laohu8.com/highlight/detail?id=2531200277","media":"上观新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531200277?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 17:24","pubTimestamp":1745918697,"startTime":"0","endTime":"0","summary":"国家药品监督管理局药品审评中心昨天正式受理百济神州在研BCL2抑制剂索托克拉片的新药上市申请，并已纳入优先审评程序，拟用于治疗既往接受过治疗的慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）成人患者。索托克拉是百济神州自主研发的新一代BCL2抑制剂，也是百济神州继泽布替尼之后有望面市的又一款血液肿瘤的自研产品，有望进一步夯实百济神州在CLL/SLL治疗领域的研发实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293392945536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1588","06160","LU1969619763.USD","BK1161","LU2328871848.SGD","BK1500","LU0588546209.SGD","LU0307460666.USD","BK4139","ONC"],"gpt_icon":0},{"id":"2531271089","title":"索托克拉上市申請獲受理 百濟神州又一款血液腫瘤自研產品有望面市","url":"https://stock-news.laohu8.com/highlight/detail?id=2531271089","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531271089?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 16:28","pubTimestamp":1745915280,"startTime":"0","endTime":"0","summary":"索托克拉是百济神州自主研发的新一代BCL2抑制剂，也是百济神州继泽布替尼之后有望面市的又一款血液肿瘤的自研产品，或将进一步夯实百济神州在CLL/SLL治疗领域的研发实力。资料显示，CLL是一种危及生命的B淋巴细胞恶性肿瘤，是成人血液肿瘤最常见的类型之一。索托克拉作为百济神州自主研发的新一代 BCL2 抑制剂，旨在阻断可帮助肿瘤细胞存活的BCL2蛋白。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042916381294e73c09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042916381294e73c09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","06160","ONC","BK0239"],"gpt_icon":0},{"id":"2531573242","title":"百濟神州2024年虧損減少至49.8億元，收入增長56.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531573242","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531573242?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 12:48","pubTimestamp":1745902091,"startTime":"0","endTime":"0","summary":"4月28日，百济神州(688235)公布2024年年报，公司营业收入为272.1亿元，同比上升56.2%；归母净利润自去年同期亏损67.2亿元变为亏损49.8亿元，亏损额有所减少；扣非归母净利润自去年同期亏损96.8亿元变为亏损53.8亿元，亏损额有所减少；经营现金流净额为-12.59亿元，同比增长83.8%；EPS(全面摊薄)为-3.5948元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293392632734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","BK1588","LU2328871848.SGD","LU0307460666.USD","BK1161","LU0588546209.SGD","ONC","06160","BK4139","BK1500","LU1969619763.USD"],"gpt_icon":0},{"id":"2531212816","title":"百濟神州4月28日成交額為6230.10萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531212816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531212816?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 10:15","pubTimestamp":1745892949,"startTime":"0","endTime":"0","summary":"美东时间2025年4月28日，百济神州成交额为6230.10万美元，成交额较昨日减少48.17%，当日成交量为24.81万股。百济神州于2025年4月28日涨1.86%，报249.46美元，该股过去5个交易日涨8.83%，年初至今涨35.05%，过去60日涨9.95%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429101600a46b521f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429101600a46b521f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2531821605","title":"港股創新藥板塊盤初走高，泰凌醫藥(01011.HK)漲近7%，石藥集團(01093.HK)漲超4%，百濟神州(06160","url":"https://stock-news.laohu8.com/highlight/detail?id=2531821605","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531821605?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 09:49","pubTimestamp":1745891393,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0417516738.SGD","LU1226288253.USD","HSTECH","159992","IE00B5MMRT66.SGD","02269","07226","LU0359201612.USD","IE0008369823.USD","LU2328871848.SGD","BK4614","BK1141","LU0823426308.USD","LU1226287792.SGD","LU1960683339.HKD","LU0516423091.SGD","LU1688375341.USD","LU0051755006.USD","IE00BZ08YR35.GBP","LU1720050803.USD","06978","688235","LU0348825331.USD","LU0456846285.SGD","LU0823426480.USD","LU0856984785.SGD","LU1152091754.HKD","ONC","YANG","603127","BK1576","01011","BK1161","06127","BK1610","BK1583","LU0880133367.SGD","LU1008478684.HKD","LU1880383366.USD","LU0819121731.USD","LU0708995583.HKD","01093","HSCEI","LU1226287529.USD","LU0588546209.SGD","IE00B031HY20.USD","06160","LU0140636845.USD","BK1588","SG9999004220.SGD"],"gpt_icon":0},{"id":"2531292252","title":"百濟神州(06160)因受限制股份單位獲歸屬而發行約10.29萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531292252","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531292252?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 08:35","pubTimestamp":1745886903,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，该公司于2025年4月28日因根据股权计划授出的受限制股份单位获归属而发行约10.29万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","LU1969619763.USD","BK1500","06160","LU2328871848.SGD","688235","ONC","BK1583","BK1161","BK4139","BK1588","BK0239","LU0588546209.SGD"],"gpt_icon":0},{"id":"2531230616","title":"百濟神州(688235.SH)發佈2024年度業績，營業收入272.14億元，同比增長56.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531230616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531230616?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 00:55","pubTimestamp":1745859336,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(688235.SH)发布2024年年度报告，公司2024年度营业收入272.14亿元，同比增长56.19%。报告期内，公司专注于创新药品的研发、生产及商业化，生产经营活动正常推进，现金流情况良好。公司已经在研究、临床开发、商业化及生产方面建立一定的竞争优势，这些竞争优势旨在推动公司的业务迈向未来。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2530235209","title":"美股異動 | 百濟神州(ONC.US)漲逾2% 機構：中國內地創新藥出海不受關稅影響","url":"https://stock-news.laohu8.com/highlight/detail?id=2530235209","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530235209?lang=zh_tw&edition=fundamental","pubTime":"2025-04-28 23:15","pubTimestamp":1745853341,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，百济神州(ONC.US)涨逾2%，报251.10美元。招银国际认为，跨国公司(MNC)购买中国内地创新药资产的热情不减，将持续成为中国内地创新药出海的重要动力。受到关税等地缘政治因素影响，以及集采的逐步推进，国产替代将加速演进，利好国产设备龙头厂商。此外，中国内地创新药出海主要途径为授权出海模式，并不涉及实际产品出口，因此不受关税影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1588","BK1583","BK4139","LU0307460666.USD","LU1969619763.USD","BK1500","ONC","LU2328871848.SGD","688235","BK1161","159992","06978","BK1574","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"2530938119","title":"百濟神州4月25日成交額為1.20億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530938119","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530938119?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 10:14","pubTimestamp":1745633676,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，百济神州成交额为1.20亿美元，成交额较昨日增加2.12%，当日成交量为48.81万股。百济神州于2025年4月25日跌4.4%，报244.9美元，该股过去5个交易日涨6.03%，年初至今涨32.59%，过去60日涨8.02%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101447a46792f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101447a46792f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2530522331","title":"“藏頭詩”挑起醫藥暗戰，恆瑞醫藥急了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2530522331","media":"达摩财经Pro","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530522331?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 23:56","pubTimestamp":1745596571,"startTime":"0","endTime":"0","summary":"截至4月25日，恒瑞医药还未对此事做出说明。以PD-1产品获批时间区分，君实生物、信达生物、恒瑞医药和百济神州被誉为\"PD-1四小龙\"。而恒瑞医药并未在财报中披露卡瑞利珠单抗的销售额。自年初至今，百济神州涨幅超48%，恒瑞医药涨幅为9.52%。截至4月25日，百济神州最新市值为3348.14亿元，恒瑞医药最新市值为3206.72亿元。2024年，百济神州核心产品泽布替尼成为国内首款“全球10亿美元俱乐部”成员药品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426002225a4670950&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426002225a4670950&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","688235","BK1515","BK1583","BK1588","06160","LU1969619763.USD","BK1161","LU2328871848.SGD","600276","BK1500","LU0307460666.USD","LU0588546209.SGD","BK1574","ONC"],"gpt_icon":0},{"id":"2530467926","title":"康方生物為什麼盯上百濟神州？","url":"https://stock-news.laohu8.com/highlight/detail?id=2530467926","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530467926?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 13:30","pubTimestamp":1745559047,"startTime":"0","endTime":"0","summary":"康方生物又赢了一次。但这一次康方生物选择了国产PD-1替雷利珠单抗做对手，这是为什么？在这一消息公布后，康方生物股价连涨两日，市值增长超百亿港元。康方生物为何选择百济神州的品种？上述人士告诉健识局：康方生物的想法可能是挑最强的打。在2024年ESMO年会上，百济神州公布的RATIONALE-307四年随访数据显示，替雷利珠单抗联合化疗组均较化疗显著延长了PFS。不过，在公告中康方生物并没有提到此次临床试验有关OS的数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425133313a46655ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425133313a46655ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC"],"gpt_icon":0},{"id":"2530943219","title":"百濟神州4月24日成交額為1.18億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530943219","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530943219?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 10:14","pubTimestamp":1745547245,"startTime":"0","endTime":"0","summary":"美东时间2025年4月24日，百济神州成交额为1.18亿美元，成交额较昨日增加9.21%，当日成交量为45.96万股。百济神州于2025年4月24日涨2.82%，报256.16美元，该股过去5个交易日涨12.28%，年初至今涨38.68%，过去60日涨13.01%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425101410a6c7673d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425101410a6c7673d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2529952490","title":"又一次“頭對頭”勝出！康方生物雙抗藥物療效“擊敗”百濟神州PD-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2529952490","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529952490?lang=zh_tw&edition=fundamental","pubTime":"2025-04-23 16:41","pubTimestamp":1745397660,"startTime":"0","endTime":"0","summary":"早间，康方生物宣布，公司双抗药物依沃西单抗又一次在头对头试验中战胜了PD-1，这次挑战的对象是百济神州的替雷利珠单抗。4月23日，百济神州A股股价下跌1.42%。依沃西是康方生物自主研发的、全球首创PD-1/VEGF双特异性肿瘤免疫治疗药物。康方生物的依沃西选择对标的这两款PD-1单抗，都有一定的代表性。百济神州的替雷利珠单抗在中国，已取得领先的PD-1市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042316430794df5305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042316430794df5305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","06160","BK4139","BK4023","09926","PD","LU1169590202.USD","688235","ONC"],"gpt_icon":0},{"id":"2529513461","title":"百濟神州4月22日成交額為1.81億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529513461","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529513461?lang=zh_tw&edition=fundamental","pubTime":"2025-04-23 10:13","pubTimestamp":1745374407,"startTime":"0","endTime":"0","summary":"美东时间2025年4月22日，百济神州成交额为1.81亿美元，成交额较昨日增加178.00%，当日成交量为72.24万股。百济神州于2025年4月22日涨10.27%，报252.77美元，该股过去5个交易日涨4.13%，年初至今涨36.85%，过去60日涨13.82%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423101329a6c4895a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423101329a6c4895a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2529502592","title":"康方生物在一項臨牀三期試驗中贏了百濟神州的PD-1抗體聯合療法","url":"https://stock-news.laohu8.com/highlight/detail?id=2529502592","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529502592?lang=zh_tw&edition=fundamental","pubTime":"2025-04-23 09:38","pubTimestamp":1745372280,"startTime":"0","endTime":"0","summary":"康方生物双抗药物依沃西又一次在头对头试验中战胜了PD-1，这次的对手是百济神州的替雷利珠单抗。在此次头对头试验中，依沃西联合化疗把替雷利珠单抗联合化疗作为对照组。康方生物表示，HARMONi-6临床试验共入组532例受试者，中央型鳞癌占比约为63%，与真实世界患者分布一致。与治疗相关的严重不良反应发生率以及三级及以上出血事件发生率与对照组相似。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423094231a463341e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169590202.USD","BK4023","PD","ONC","LU1169589451.USD","BK4139"],"gpt_icon":0},{"id":"2529371912","title":"百濟神州(ONC)盤前漲超8% 機構升其目標價至317美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529371912","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529371912?lang=zh_tw&edition=fundamental","pubTime":"2025-04-22 18:47","pubTimestamp":1745318837,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨超8%，截至发稿，报249.32美元。消息面上，摩根大通分析师杰西卡·费伊维持百济神州评级为增持，并将目标价从311美元上调至317美元。此外，国盛证券表示，公司产品已实现自主出海，全球商业化能力强劲，产品管线聚焦潜在同类最佳目标，创新性突出。该行看好公司长期发展。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDg5MDljMjM3Zjg4MTM1NjQzMDIzNjY=.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287722","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688235","06160","ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-15","current":-60.573233,"percent":0.055556,"low":-64.911375,"twenty":-43.435784,"median":-39.777828,"eighty":-28.825561,"high":-22.805663,"avg":-37.671721,"sd":9.718771,"marketCap":23766876949},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-15","current":-60.573233,"twenty":-43.435784,"median":-39.777828,"eighty":-28.825561,"marketCap":23766876949}],"updateTime":1747389568009}}}